Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | CTSK | P43235 | 9/20 | 0.36 |
| ▸ | CTSS | P25774 | 8/20 | 0.36 |
| ▸ | CTSB | P07858 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21398708 | 0.84 | CTSL (0.36) | CTSLCTSKCTSSMEN1MAPK1 | |
| SCHEMBL2394821 | 0.83 | CTSL (0.59) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL1586413 | 0.80 | CTSL (0.53) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL29056863 | 0.77 | CTSL (0.51) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL22380386 | 0.77 | CTSL (0.40) | CTSLMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL14499840 | 0.76 | CTSL (0.50) | CTSLCTSKCTSSCTSBCTSD | |
| SCHEMBL31714895 | 0.75 | CTSL (0.38) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL23863121 | 0.74 | CTSL (0.42) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL23863123 | 0.74 | CTSL (0.45) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL23863206 | 0.74 | CTSL (0.42) | CTSLCTSKCTSSMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097871-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4008405-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| US-20200268730-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097871-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | LPAR1, LPAR2, LPAR3 | CTSL 3735/4885CTSK 3651/4885CTSS 4024/4885 |
| US-20200268730-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | HDGF, FABP1, NR1H4 | CTSL 1754/4885CTSK 2291/4885CTSS 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.